Pacira BioSciences, Inc.

Pacira BioSciences develops, manufactures, markets, and sells non-opioid pain management solutions. Products include EXPAREL, ZILRETTA, and iovera system. The company has a development agreement with Aratana Therapeutics for NOCITA. Pacira was previously known as Pacira Pharmaceuticals before changing its name in 2019.

Overview

Sector

Pharmaceutical

Target Price

0.0 USD

Current Price

21.0 USD

Potential

-100%

Strengths

Price to book ratio (1.25) is lower than the sector mean (733.70).
EV/EBITDA (6.65) is lower than the sector mean (51.86).
Price to free cash flow (5.43) is lower than the sector mean.
Strong EBITDA Margin of 27.47%.

Weaknesses

With a depreciation Potential of -100.00%, based on our fundamental analysis, it suggests the stock may be overvalued.
Analysts expect revenues to decline in the coming year.

Indicator	Value
PER	100.0
EV/EBITDA	6.6
Price/Free Cash Flow'	5.4
ROIC	13.9%
Net Debt/EBITDA	1.6

Pacira BioSciences, Inc.

Overview

Strengths

Weaknesses

Key Financial Data